Pcr after neoadjuvant chemotherapy
Splet04. apr. 2024 · In their article published in the JAMA Oncology, the investigators sought to determine the prognostic significance of pCR on survival outcomes in STS for patients receiving neoadjuvant chemoradiotherapy in RTOG 9514 or preoperative image-guided radiotherapy alone in RTOG 0630 and provide a long-term update of RTOG 0630. RTOG … Splet12. dec. 2024 · High Oncotype DX RS was associated with pCR after NCT in this national cohort of ER-positive, HER2-negative patients. Oncotype DX testing could help to identify patients most suited for NCT and should be considered for incorporation into the multidisciplinary decision-making process.
Pcr after neoadjuvant chemotherapy
Did you know?
SpletPurpose: To retrospectively analyze the efficacy and toxicity of epirubicin plus cyclophosphamide followed by docetaxel (EC-D) and epirubicin plus cyclophosphamide … Splet17. maj 2024 · MRI performance in detecting pathologic complete response (pCR) post-neoadjuvant chemotherapy (NAC) in breast cancer has been previously explored. However, since tumor response varies by molecular subtype, it is …
Splet22. sep. 2016 · Patients with TNBC have increased pCR rates compared with non-TNBC, and those with pCR have excellent survival. However, patients with RD after neoadjuvant chemotherapy have significantly worse survival if they have TNBC compared with non-TNBC, particularly in the first 3 years. INTRODUCTION Splet22. jun. 2024 · In HR-positive/HER2-negative cancers, the clinical significance of pCR after neoadjuvant chemotherapy is not verified. Pooled analysis showed pCR was positively associated with event-free survival (HR 0.49, 95% CI, 0.33–0.71) and OS (0.43, 0.23–0.71), weaker than HER2-positive and TN breast cancers ( 27 ).
Splet08. feb. 2024 · A retrospective cohort study including all breast cancer patients with axillary lymph node metastases at presentation who received neoadjuvant chemotherapy (NACT) resulting in pathological complete response (pCR) between January 2013 and December 2024 at a high-volume tertiary referral centre operating on 2000 breast cancer patients … Splet07. jan. 2024 · Patients with pathologic complete response (pCR) after neoadjuvant chemotherapy have been shown to have improved disease-free survival (DFS) and overall …
SpletTriple-negative breast cancer (TNBC) is a heterogeneous disease with varying responses to neoadjuvant chemotherapy (NAC). The identification of biomarkers to predict NAC …
Splet15. feb. 2024 · Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery [abstract]. 10 位能驻值原理Splet04. maj 2024 · Neoadjuvant systemic therapy (NST) that contains trastuzumab in addition to neoadjuvant chemotherapy leads to high pathologic complete response (pCR) rates in patients with human epidermal growth factor receptor 2 (HER2)-positive invasive breast cancer (IBC) [1,2,3].Even higher pCR rates are seen when a trastuzumab-containing … 10 倍梯度稀释法Splet04. jan. 2024 · Achieving pCR following neoadjuvant chemotherapy (NACT) is a desirable outcome, ... Muller V., du Bois A., Kuhn T., et al. Pathologic complete response after … 10 個Splet31. dec. 2024 · Objective . Earlier research has illustrated prognostic significance of pathologic complete response (pCR) in neoadjuvant therapy (NAT) for breast cancer, … 10 倍交叉验证SpletThe only factor predictive of pCR was squamous-cell carcinoma. Identifying molecular predictive markers for pCR may help in distinguishing patients likely to benefit from … 10 値上げ 計算Splet05. apr. 2024 · Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions. 30 eligible patients will be enrolled and 3 cycles of Toripalimab 240mg ... 10 兆字节Splet08. feb. 2024 · Background It is difficult to determine pathological complete response (pCR) before surgery in clinical complete response (cCR) cases by imaging alone. We designed a prospective study to evaluate whether a breast tissue marker placed in a tumor before neoadjuvant chemotherapy (NAC) can predict a pCR, possibly removing the need for … 10 公式